. . . . . . . . . . . . . . . . . . . . . . . . . . . . . "Interakce s\u00A0l\u00E9\u010Div\u00FDmi p\u0159\u00EDpravky\nJe zn\u00E1mo, \u017Ee n\u011Bkter\u00E9 l\u00E1tky zvy\u0161uj\u00ED nebo sni\u017Euj\u00ED hladiny cyklosporinu v\u00A0plazm\u011B nebo celkov\u011B v\u00A0krvi t\u00EDm, \u017Ee inhibuj\u00ED nebo indukuj\u00ED enzymy \u00FA\u010Dastn\u00EDc\u00ED se metabolizmu cyklosporinu, co\u017E se t\u00FDk\u00E1 zvl\u00E1\u0161t\u011B cytochromu P450.\nL\u00E9\u010Div\u00E9 p\u0159\u00EDpravky, kter\u00E9 mohou zvy\u0161ovat koncentraci cyklosporinu v\u00A0krvi t\u00EDm, \u017Ee inhibuj\u00ED enzymy odpov\u011Bdn\u00E9 za jeho metabolizmus a vylu\u010Dov\u00E1n\u00ED (p\u0159edev\u0161\u00EDm cytochrom P450 IIIA):\nPeror\u00E1ln\u00ED antikoncep\u010Dn\u00ED prost\u0159edky, glukokortikoidy, makrolidov\u00E1 antibiotika (erytromycin, klaritromycin, josamycin), imidazolov\u00E1 a triazolov\u00E1 antimykotika (metronidazol, flukonazol, itrakonazol, ketokonazol), antagonist\u00E9 H2 receptor\u016F (ranitidin, cimetidin), blok\u00E1tory kalciov\u00FDch kan\u00E1l\u016F (diltiazem, nifedipin, nimodipin, nikardipin, verapamil), fluorochinolony, pristinamycin, doxycyklin, propafenon, allopurinol, bromokriptin, danazol, metoklopramid, amiodaron, kyselina ursodeoxycholov\u00E1, inhibitory prote\u00E1zy."@cs . . . . . . . . . . "21412"^^ . . . . . "1"^^ . . . "20487"^^ . .